Literature DB >> 17456474

Osteopontin overexpression inhibits in vitro re-endothelialization via integrin engagement.

Daria Leali1, Emanuela Moroni, Federico Bussolino, Marco Presta.   

Abstract

The extracellular matrix protein osteopontin (OPN) plays a nonredundant role in atherosclerosis and restenosis. Here we investigated the impact of OPN up-regulation in an in vitro model of re-endothelialization after mechanical injury of the endothelial cell monolayer. Murine aortic endothelial (MAE) cells interact via alpha(v) integrins with the integrin-binding Arg-Gly-Asp OPN sequence and adhere to immobilized OPN. On this basis, MAE cells were stably transfected with a wild-type OPN cDNA (OPN-MAE cells), with an OPN mutant lacking the Arg-Gly-Asp sequence (DeltaRGD-OPN-MAE cells), or with vector alone (mock-MAE cells). When compared with mock-MAE and DeltaRGD-OPN-MAE cells, OPN-MAE cells showed a reduced sprouting activity in fibrin gel, a reduced motility in a Boyden chamber assay, and a reduced capacity to repair the wounded monolayer. Accordingly, OPN-MAE cells at the edge of the wound were unable to form membrane ruffles, to reorganize their cytoskeleton, and to activate the focal adhesion kinase and the small GTPase Rac1, key regulators of the cell entry into the first phase of the cell migration cycle. Accordingly, wounded OPN-MAE cells failed to activate the intracellular signals RhoA and ERK1/2, involved in the later phases of the cell migration cycle. Also, parental MAE cells showed reduced re-endothelialization after wounding when seeded on immobilized OPN and exhibited increased adhesiveness to OPN-enriched extracellular matrix. In conclusion, OPN up-regulation impairs re-endothelialization by inhibiting the first phase of the cell migration cycle via alpha(v) integrin engagement by the extracellular matrix-immobilized protein. This may contribute to the adverse effects exerted by OPN in restenosis and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17456474     DOI: 10.1074/jbc.M606938200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor.

Authors:  Anne-Sophie Belzacq-Casagrande; Florence Bachelot; Catherine De Oliveira; Séverine Coutadeur; Florence Maurier-Mahé; Emeline Throo; Cédric Chauvignac; Laure Pognante; Angélique Petibon; Thierry Taverne; Eric Beausoleil; Bertrand Leblond; Matthew P Pando; Laurent Désiré
Journal:  Invest New Drugs       Date:  2012-08-10       Impact factor: 3.850

2.  Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry.

Authors:  Jing Li; Guang-Zhi Yang; Zi-Man Zhu; Zhi-Yong Zhou; Lin Li
Journal:  Exp Ther Med       Date:  2012-01-30       Impact factor: 2.447

Review 3.  Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification.

Authors:  Hyun-Ju Cho; Hyun-Jai Cho; Hyo-Soo Kim
Journal:  Curr Atheroscler Rep       Date:  2009-05       Impact factor: 5.113

4.  Distribution of alkaline phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcified human carotid atheroma.

Authors:  Catherine L Higgins; Salim Isbilir; Pamela Basto; Iou Yih Chen; Muthiah Vaduganathan; Periyanan Vaduganathan; Michael J Reardon; Gerald Lawrie; Leif Peterson; Joel D Morrisett
Journal:  Protein J       Date:  2015-10       Impact factor: 2.371

5.  Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring.

Authors:  Ryoichi Mori; Tanya J Shaw; Paul Martin
Journal:  J Exp Med       Date:  2008-01-07       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.